Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Flavia SalviDivision of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy;

Stefano LuminariHematology Unit, Azienda Unità Sanitaria Locale IRCCS, Reggio Emilia, Italy; ;Surgical, Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy;

Alessandra TucciDivision of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy;

Stefania MassiddaHematology and Transplant Center, Ospedale Oncologico di Riferimento Regionale Armando Businco, Azienda Ospedaliera Brotzu, Cagliari, Italy;

Anna Marina LiberatiOncohematology and autotransplantation Unit, Azienda Ospedaliera Santa Maria, Terni, Italy;

Caterina StelitanoDivision of Hematology, Azienda Ospedaliera “Bianchi Melacrino Morelli”, Reggio Calabria, Italy;

Manuela ZanniDivision of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy;

Alessandro ReDivision of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy;

Riccardo CenturioniInternal medicine and hematology Unit, Azienda Sanitaria Unica Regionale Marche AV3, Civitanova Marche, Italy;

Roberto FreiloneDepartment’s Structure of Hematology, Ivrea, Italy;

Gerardo MusuracaHematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (FC);

Luca NassiDivision of Hematology Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità, Novara, Italy;

Caterina PattiDepartment of Hematology I, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy;

Annalisa ArcariHematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, Piacenza, Italy;

Monica TaniHematology, S. Maria delle Croci Hospital, Ravenna, Italy;

Alessandro PulsoniDepartment of Cellular Biotechnologies and Hematology, Policlinico Umberto I "Sapienza" University of Rome, Roma, Italy;

Vincenzo PavoneDepartment of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy;

Stefano VolpettiDepartment of Haematology, DISM Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine, Italy;

Annalisa PeliDivision of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy;

Andrea EvangelistaClinical and Evaluative Epidemiology Unit, AOU Città della Salute e della Scienza di Torino e CPO Piemonte, Torino, Italy;

Michele SpinaDivision of Medical Oncology and Immunorelated Tumors, National Cancer Institute, Aviano, Italy

Marco LadettoDivision of Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy;

Francesco MerliHematology Unit, Azienda Unità Sanitaria Locale IRCCS, Reggio Emilia, Italy; Correspondence[email protected]

show all

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Articles from other publishers (8)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Citations (8)

Articles from other publishers (8)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date